Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000633:toxicity; D008875:Middle Aged; D009120:Muscle Cramp / Q000139:chemically induced; D009362:Neoplasm Metastasis; D010166:Palliative Care; D012075:Remission, Spontaneous; D013997:Time Factors; D014202:Tremor / Q000139:chemically induced
D008525:Medroxyprogesterone